CompletedNCT01303861
Adaptive Medication Strategies for Quitting Smoking
About this title
Read the official source — NCT01303861Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Charlotte and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 702
- Sponsor
- Duke University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01303861
- Official title
Show the full official title
Concurrent Bupropion / Varenicline for Smoking Cessation
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Charlotte · Durham · Raleigh
1 more locations
- Winston-Salem
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Duke University, a university.
Did this study involve medication?
Yes. The study involved medication, including Varenicline, Bupropion, Nicotine patches and Nicotine Inhaler.
Who was this study for?
Listed age limits: 18 years to 65 years.
